Abbott Laboratories Corporation

Akwete L Adjei

Pramod K Gupta

Dennis Y Lee

Mou-Ying Fu Lu

Edwin Samuel Johnson

Anthony J Hlinak

James W Kesterson

Kennan C Marsh

Lois R Sherry

Barbara A Danks

Jack Zheng

Hillard W Johnson

Vivian Wu

The present invention relates to methods and formulations for administering a dopamine agonist to the airways of a patient. The preferred dopamine agonist is selected from (5aR-trans)-4,5,6,7,11b-hexahydro-2-propylbenzo&lsqb;f&rsqb;thieno&lsqb;2,3-c&rsqb;quinoline- 9,10) -diol, diacetate (ester) hydrochloride. The delivery method relates to certain aerosol formulations and liquid formulations which are administered into the airways to provide effective delivery of the dopamine agonists to the receptor.

Formulations for pulmonary delivery of dopamine agonists

The present invention provides a uniform dispersion in aqueous medium of droplets comprising: (a) a core comprising water, a non-toxic C.sub.2 -C.sub.5 alkanol, a water-soluble drug, and a surfactant, and (b) a coating surrounding the core comprising one or more pharmaceutically acceptable oils. The compositions of the present invention are particularly useful for the oral delivery of therapeutic agents because of their potential for taste masking, prolonged action, and protection of the drug against the external environment and enzyme entrapment.

Delivery system for pharmaceutical agents encapsulated with oils

The present invention provides a process for the continuous milling of aerosol pharmaceutical formulations which contain solids by milling in the aerosol propellant.

Process for the continuous milling of aerosol pharmaceutical

The present invention provides a process and apparatus for the continuous milling of aerosol pharmaceutical formulations which contain solids by milling in the aerosol propellant.

Apparatus for the continuous milling of aerosol pharmaceutical

Pharmaceutical compositions for aerosol delivery comprising a medicament, a non-chlorofluorocarbon propellant and a protective colloid, as well as a method for preparing such compositions in which the aggregation of the particles is prevented without the use of surfactants or cosolvents.

Aerosol drug formulations for use with non CFC propellants

Pharmaceutical compositions for aerosol delivery comprising (a) a medicament, (b) a non-chlorofluorocarbon propellant, and (c) a polyglycolized glyceride having a hydrophilic lipophilic balance of between and including 6 and 14, wherein the medicament is present in a concentration of between about 0.05% and about 5% by weight and the polyglycolized glyceride is present in a concentration of between about 0.001% and about 10% by weight, the nonchlorofluorocarbon propellant is selected from the group consisting of HCFC 123, HCFC 124, HCFC 141b, HCFC 225, HCFC 125, FC-C 51-12, DYMEL A, DYMEL 152a, HFC 134a and HFC 227ea in which unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents.

Aerosol drug formulations containing polyglycolyzed glycerides

Pharmaceutical compositions for aerosol delivery comprising (a) a medicament, (b) a non-chlorofluorocarbon propellant, and (c) a vegetable oil or a pharmaceutically acceptable derivative thereof, as well as a method for preparing such compositions in which unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents.

Aerosol drug formulations containing vegetable oils

A collapsible, articulated actuator for the aerosol delivery of a medicament comprised comprises an elliptical expansion chamber hingedly and slideably attached to an aerosol cannister-receiving portion in a manner which permits the cannister-receiving portion to be telescoped into the expansion chamber for storage. In use, the cannister-receiving portion is pulled out of the expansion chamber and rotated until it locks into position at an angle ranging between about 102.degree. and 110.degree. with the expansion chamber. The angle between the two portions of the actuator, the volume of the expansion chamber, and the degree of elliptical eccentricity of the expansion chamber are optimized for maximum delivery of an aerosolized medicament to the deep lungs of a patient.

Aerosol inhalation device having slideably and rotatably connected

The invention relates to novel solution and suspension aerosol formulations comprising LHRH analogs.

LHRH analog formulations

The invention relates to novel aerosol formulations comprising LHRH analogs, a lipophilic counterion, solvent and propellant and, optionally, surfactant, valve lubricant, an antioxidant and flavor and fragrance.

Growing community of inventors

Wadsworth, IL, United States of America

Akwete L Adjei